Physician profile
Michael E Barness
NPI 1730478991
$5,236.26
in general payments reported to CMS, 2019-2025
22 companies · $1,353 in 2025
The $1,353 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $834 · 2020: $48.19 · 2021: $27.53 · 2022: $163 · 2023: $1,338 · 2024: $1,472 · 2025: $1,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,163.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $791.96 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $765.93 | 2022-2025 | Qelbree, Qelbree |
| Abbvie INC. | $672.43 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $473.41 | 2023-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $339.19 | 2023-2025 | Quviviq, Quviviq |
| Lundbeck LLC | $338.73 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $299.56 | 2023-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $271.13 | 2019-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $263.47 | 2022-2024 | Auvelity |
| Sunovion Pharmaceuticals INC. | $256.52 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $153.01 | 2019-2023 | Ingrezza |
| Alkermes, INC. | $130.10 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Corium, LLC | $101.03 | 2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $86.01 | 2019 | |
| Allergan, INC. | $66.31 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $47.52 | 2025 | Jornay Pm |
| Owp Pharmaceuticals, INC. | $46.17 | 2023-2025 | Subvenite, Lamotrigine |
| Teva Pharmaceuticals USA, INC. | $43.93 | 2019-2024 | Austedo Xr |
| Neos Therapeutics, Lp | $33.28 | 2024 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $30.23 | 2024 | |
| Bausch Health US, LLC | $13.18 | 2024 | Wellbutrin, Aplenzin |
| Neuronetics, INC. | $13.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Barness listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.